Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients

Microvascular Research

Volumn 80, Issue 3, 2010, Pages 440-444

  Naskret, Dariusz ^a   Zozulinska Ziolkiewicz, Dorota A ^a   Dankowski, Rafal ^a   Wysocki, Henryk ^a   Wierusz Wysocka, Bogna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Albuminuria; Diabetes mellitus type1; Myocardial ischemia; Vascular endothelial growth factor

Indexed keywords

ATROPINE; DIPYRIDAMOLE; DOBUTAMINE; VASCULOTROPIN;

ADULT; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE DURATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; EXERCISE TEST; FEMALE; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART WORK; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; REST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; TREADMILL EXERCISE;

ADULT; AGE FACTORS; ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MYOCARDIAL PERFUSION IMAGING; ODDS RATIO; POLAND; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 78249266275     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.07.009     Document Type: Article

References (39)

1. Agardh C.D., Agardh E., Torffivit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5year follow-up study of 442 adult patients in routine care. Diabetes Res. Clin. Pract. 1997, 35:113-121.
2. Ayerden Ebinc F., Haksun E., Ülver D.B., Koc E., Erten Y., Altok K.R., Bali M., Turgay A., Sindel S. The relationship between vascular growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Inter. Med. 2008, 47:1511-1516.
3. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
4. Berman D.S., Hachamovitch R., Kiat H., et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J. Am. Coll. Cardiol. 1995, 26:639-647.
5. Berman D.S., Kang X., Van Train K.F., et al. Comparative prognostic value of automatic quantitative analysis versus semiquantitative visual analysis of exercise myocardial perfusion single photon emission computed tomography. J. Am. Coll. Cardiol. 1998, 32:1987-1995.
6. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., et al. Urinary albumin excretion an independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1992-1997.
7. Caprio S., Wong S., Alberti K.G.M.M., King G. Cardiovascular complications of diabetes. Diabetologia 1997, 40:78-82.
8. Chiarelli F., Spagnoli A., Basciani F., et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet. Med. 2000, 17:650-656.
9. Committee of the Task Force Heart rate variability standards of measurement, physiological interpretation, and clinical use. Circulation 1996, 93:1043-1065.
10. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 21:199-204.
11. Diercks G.F.H., Stroes E.S.G., van Boven A.J., et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilatation, in apparently healthy subjects. Atherosclerosis 2002, 163:121-126.
12. Ferrara N., Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001, 106:148-156.
13. Fletcher G.F., Balady G., Victor F., Froelicher V.F., et al. Exercise standards. A statement for healthcare professionals from the American Heart Association. Circulation 1997, 96:345-354.
14. Garcia M.J., McNamara P.M., Gordon T., Kannell W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up. Diabetes 1974, 23:105-111.
15. Gianrossi R., Detrano R., Mulvihill D., et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989, 80:87-98.
16. Gibbons R.J., Balady G.J., Beasley J.W., et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation 1997, 96:345-354.
17. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J. Am. Coll. Cardiol. 2002, 40:1531-1540.
18. Henry T.D., Annex B.H., McKendall G.R., et al. The VIVA Trial; vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003, 107:1359-1365.
19. Jager A., van Hinsbergh V.W.M., Kostese P.J., et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2002, 22:593-598.
20. Kang X., Berman D.S., Lewin H.C., et al. Incremental prognostic value of myocardial perfusion single photon emission computer tomography in patients with diabetes mellitus. Am. Heart J. 1999, 138:1025-1032.
21. Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1014-1019.
22. Lydakis C., Lip G.Y.H. Microalbuminuria and cardiovascular risk. Q. J. Med. 1998, 91:381-391.
23. Meyer C., Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes. Am. J. Cardiol. 1997, 80(3A):94A-101A.
24. Mogensen C.E., Poulsen P.L. Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int. 2004, 66(suppl. 92):S40-S41.
25. Olson J.C., Erbey J.R., Williams K.V., et al. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann. Epidemiol. 2002, 12:331-337.
26. Paulson D.J. The diabetic heart is more sensitive to ischemic injury. Cardiovasc. Res. 1997, 34:104-112.
27. Pumprla J., Howorka K., Groves D., et al. Functional assessment of heart rate variability: physiological basis and practical applications. Int. J. Cardiol. 2002, 84:1-14.
28. Resnick H.E., Howard B.V. Diabetes and cardiovascular disease. Annu. Rev. Med. 2002, 53:245-267.
29. Retnakaran R., Zinman B., 2008. Type 1 diabetes, hyperglycaemia, and the heart. Lancet, 24, 371(9626), 1790-9.
30. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 2001, 47:403-411.
31. Rutter M.K., Wahid S.T., McComb J.M., Marshall S.M. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. JACC 2002, 40:56-61.
32. Schmiedel O., Schroeter M.L., Harvey J.N. Microalbuminuria in type 2 diabetes indicates impaired microvascular vasomotion and perfusion. Am. J. Physiol. Heart Circ. Physiol. 2007, 293(6):H3424-H3431.
33. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
34. Stehouwer C.D.A., Lambert J., Donker A.J.M., van Hinsbergh V.W.M. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 1997, 34:55-68.
35. Timmis A.D. Diabetic heart disease: clinical considerations. Heart 2001, 85:463-469.
36. Travin M.I., Flores A.R., Boucher C.A., et al. Silent versus symptomatic ischemia during a thallium 201 exercise test. Am. J. Cardiol. 1991, 68:1600-1608.
37. Turner R.C., Millns H.A., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998, 316:823-828. UKPDS Study Group.
38. van Hecke M.V., Dekker J.M., Stehouwer C.D., Polak B.C., Fuller J.H., Sjolie A.K., Kofinis A., Rottiers R., Porta M., Chaturvedi N. EURODIAB prospective complications study Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2006, 29(5):1178.
39. Weis U., Turner B., Gibney J., et al. Long-term predictors of coronary artery disease in type 1 diabetes. Q. J. Med. 2001, 94:623-630.